Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Trial Profile

Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IBS-D
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 03 Oct 2017 Primary endpoint has been met. (stool consistency response in the absence of increase in pain), according to a RedHill Biopharma media release.
    • 03 Oct 2017 Top-line results presented in a RedHill Biopharma Media Release.
    • 28 Sep 2017 According to a RedHill Biopharma media release, compny will host a conference call and webcast on October 3rd, 2017 at 9:00 a.m. EDT to discuss the top-line results from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top